• 2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% – bringing potential reach to over 23 million patients across these initiatives • Enhanced target for full carbon neutrality across all company operations and entire supply chain by 20301 • New collaboration with […]
• Roche will obtain co-development and co-commercialisation rights for pralsetinib, an investigational, precision therapy in late-stage development for people with RET-altered non-small cell lung cancer, various types of thyroid cancer and other solid tumours. • Blueprint Medicines and Roche will collaborate on the development of pralsetinib. • Roche and Blueprint Medicines will co-commercialise pralsetinib in […]
The Commission announced today that 8 large-scale research projects, aimed at developing treatments and diagnostics for the coronavirus,were selected in a fast-track call for proposals, launched in March by the Innovative Medicines Initiative (IMI), a public-private partnership. In order to fund a larger number of high-quality proposals, the Commission increased its commitment to €72 million […]
The European Commission, EMA and the European medicines regulatory network have developed a Q&A document to provide guidance to stakeholders on adaptations to the regulatory framework to address challenges arising from the COVID-19 pandemic, with a particular focus on crucial medicines for use in COVID-19 patients. The document explains some regulatory flexibilities that can be […]
Coronavirus: Statement by Ursula von der Leyen, President of the European Commission, on guidelines to ensure supply and availability of medicines here On 8 April 2020, Ursula von der Leyen, President of the European Commission, recorded a video message at the European Commission in Brussels, Belgium, on guidelines to ensure supply and availability of medicines.These guidelines […]
The European Commission, the European Medicines Agency (EMA) and national Head of Medicines Agencies (HMA) have published new recommendations for sponsors on how to manage the conduct of clinical trials in the context of the coronavirus disease (COVID-19) pandemic. The impact of the pandemic on European health systems and more broadly on society, will make […]
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Korean
Portuguese
Russian
Spanish